Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:09 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
NCT01123707 · Otsuka Pharmaceutical Development & Commercialization, Inc. · PHASE3 · terminated · last registry update 2021-12-22 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was terminated early due to Sponsor decision; no safety issues.” | – | Registry record, Otsuka Pharmaceutical Development & Commercialization, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against DRD2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-12-14Results posted on the registry: Adrianna Vlachos, MD, Trifluoperazine (NCT03966053)
- 2022-12-14Also stopped (terminated): Adrianna Vlachos, MD, Trifluoperazine (NCT03966053)
- 2022-11-04Also stopped (terminated): The University of Hong Kong, Olanzapine + Haloperidol (NCT02380118)
- 2022-11-04Also stopped (terminated): The University of Hong Kong, Olanzapine oro-dispersible 5Mg Tab + Haloperidol 2Mg encapsulated Tab (NCT03246620)
- 2022-11-01Results posted on the registry: Supernus Pharmaceuticals, Inc., SPN-810 (18 mg) + SPN-810 (36 mg) (NCT02618408)
- 2022-10-19Phase 3 first posted: Oman Medical Speciality Board, Metoclopramid ( 10mg), IM promethazine (25mg) , IM prochloroperazine( 12.5mg) (NCT05586763)
- 2022-09-07Results posted on the registry: Ferring Pharmaceuticals, Quinagolide 1080 µg + Placebo (NCT03749109)
- 2022-09-01Results posted on the registry: M.D. Anderson Cancer Center, Chlorpromazine + Haloperidol (NCT03021486)
- 2022-07-14Also stopped (terminated): Wake Forest University Health Sciences, 0.5% bupivacaine + Standard Care (NCT01785459)
- 2022-06-24Phase 3 first posted: M.D. Anderson Cancer Center, Haloperidol + Chlorpromazine (NCT05431595)
- 2022-06-14Results posted on the registry: Joseph Dib, Haloperidol + Promethazine + Chlorpromazine + Haloperidol + Promethazine (NCT03639558)
- 2022-06-08Results posted on the registry: Cycle Pharmaceuticals Ltd., Haloperidol Tablets, Mylan Pharmaceuticals Inc. + Haloperidol Tablets, Cycle Pharmaceuticals Ltd (NCT04411940)
- 2022-06-08Results posted on the registry: Cycle Pharmaceuticals Ltd., Haloperidol Tablets, Mylan Pharmaceuticals Inc. + Haloperidol Tablets, Cycle Pharmaceuticals Ltd (NCT04411953)
- 2022-05-11Also stopped (terminated): Erasmus Medical Center, Haloperidol + Placebo (NCT03628391)
- 2022-02-28Phase 3 first posted: Negovsky Reanimatology Research Institute, Sevoflurane + Propofol (NCT05259631)
- 2021-10-12Results posted on the registry: Case Western Reserve University, Haloperidol Decanoate (NCT04327843)
- 2021-10-04Phase 3 first posted: Corewell Health South, Droperidol + Haloperidol (NCT05065567)
- 2021-09-09Results posted on the registry: Juntendo University, reduction of risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazine (NCT03019887)
- 2021-04-06Phase 3 first posted: Tan Tock Seng Hospital, Haldol 2mg/ml oral solution + Olanzapine Actavis 5mg orodispersible tablet (NCT04833023)
- 2021-03-01Results posted on the registry: University of Texas Southwestern Medical Center, Lurasidone + Haloperidol (NCT02199743)
- 2021-01-19Results posted on the registry: Janssen Scientific Affairs, LLC, Aripiprazole + Haloperidol (NCT02431702)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision